Pharmacokinetics of the main capsinoid components of CH-19 Sweet extract (capsiate, dihydrocapsiate, and nordihydrocapsiate) were investigated in rats receiving a single gavage dose of extract containing 10 or 100 mg of capsinoids per kilogram in mediumchain triglyceride. Resultant blood levels of these capsinoids and a capsinoid metabolite, vanillyl alcohol, were measured in portal vein and systemic blood. Capsinoids were never detected. Portal compartment vanillyl alcohol concentrations and area under the plasma concentration versus time curve increased approximately with dose, whereas the time to maximum concentration of vanillyl alcohol was independent of dose (30 minutes post dosing), suggesting that precipitation in the stomach or intestines was unlikely. Vanillyl alcohol levels were just barely detectable in systemic plasma (5 minutes post dosing). Significant levels of vanillyl alcohol conjugates, sulfate, and glucuronide were detected in the systemic blood. Given that the orally administered capsinoids were never detected in the portal vein or systemic circulation, these compounds must be broken down (chemically or enzymatically) to vanillyl alcohol.
Capsaicin occurs naturally in plants of the Solanaceae family and is the compound mainly responsible for the pungency associated with the fruit of red pepper plants ( Figure 1 ). Capsaicin homologues are called capsaicinoids; these compounds consist of acid amides of vanillyl amine and C8 to C13 fatty acids. The major capsaicinoids in pungent red peppers are capsaicin ([E]-[4-hydroxy-3-methoxybenzyl]-8-methyl-6-nonenamide), dihydrocapsaicin, the 6,7-dihydro analogue of capsaicin and nordihydrocapsaicin, the mono-nor homologue of the acyl residue of dihydrocapsaicin 1 (Figure 1) . Recently, so-called novel capsaicinoid-like substances were found in the fruit of CH-19 Sweet, a nonpungent cultivar of Capsicum annuum L. 2 Previous work by Kobata and others 3, 4 determined the structures and named these substances capsiate (4-hydroxy-3-methoxybenzyl [E]-8-methyl-6-nonenoate; Figure 2 ), dihydrocapsiate (4-hydroxy-3-methoxybenzyl 8-methyloctanoate, DHC), and nordihydrocapsiate (4-hydroxy-3-methoxybenzyl 7-methyloctanoate), respectively. These compounds have an ester bond replacing the amide bond found in capsaicinoids (ie, between the vanillyl moiety and fatty acid chain). As a class, these novel compounds are called capsinoids. 4 The acyl residues of capsinoids are identical to those of capsaicinoids.
It has been reported that capsaicin elevates body temperature and suppresses accumulation of fat. 5, 6 However, its use to suppress accumulation of fat is limited because of its strong, pungent taste. On the other hand, capsinoids are components of CH-19 Sweet, a nonpungent cultivar of Capsicum annuum L., which has weak pungency. 3, 4 Capsiate enhances energy metabolism and suppresses body fat accumulation in mice as does capsaicin. 7 A clinical study confirmed that CH-19 Sweet elevates body temperature and increases oxygen consumption in humans. 8 The weaker pungency of capsinoids, compared with capsaicin, makes it possible to take advantage of capsinoids' pharmacology (ie, increased energy metabolism and suppression of body fat accumulation) by increasing the amount of capsinoids consumed.
A series of nonclinical studies and a single clinical study have investigated the safety considerations of CH-19 Sweet extract; in those studies, minimal to no toxicity was observed. In a single-dose gavage study in rats, transient salivation and decreased motor activity, but no lethality, were observed at the highest dose tested, the reported median lethal dose (LD 50 ) being greater than 20 mL of CH-19 Sweet extract per kilogram (equivalent to >1425 mg of capsinoids per kilogram, or >285 mg of DHC per kilogram). 9 In that same study, CH-19 Sweet extract was reportedly negative when tested for mutagenicity in in vitro and in vivo clastogenicity studies. CH-19 Sweet extract, administered daily by gavage in amounts up to 5.0 mL/kg/d (equivalent to 178 mg of capsinoids per kilogram per day or 33 mg of DHC per kilogram per day), failed to induce observable adverse effects. 10 Additional published, preclinical studies (2-generation reproduction in rats 11 and teratology in rats and rabbits 12 failed to detect adverse effects. In the only human study in which CH-19 Sweet extract was administered, 16 healthy male volunteers exhibited no clinically significant changes in physical examinations, blood pressure, heart rate, electrocardiogram, hematology, blood chemistry, and urinalysis following consumption of up to 30 mg per person. An increase in body temperature that was statistically significant but not physiologically significant was reported. 13 Safety studies of the major component of CH-19 Sweet extract, DHC, also reveal minimal to no toxicity. When a single gavage dose of commercial-grade DHC (up to 5000 mg/kg) was administered to mice, transient clinical alterations, but no lethality (LD 50 >5000 mg/kg), were observed over a 14-day period. 14 Testing with both in vitro and in vivo gene mutation assays suggested a low or extremely low likelihood of inducing genotoxicity. 15 A similar conclusion was reached when DHC was tested in the in vivo micronucleus test. 14 Teratology studies performed in rats and rabbits (high dose 1000 mg of DHC per kilogram per day) were negative for adverse findings. 16 DHC was administered by gavage (top dose 1000 mg/kg/d) to rats in two 13-week studies; neither study contained a recovery period. Kodama et al 17 concluded that the no observable adverse effect level (NOAEL) was 1000 mg/kg/d in both sexes in an oral subchronic study. In the absence of a chronic toxicity study and/or evidence of amelioration during a recovery period, Watanabe et al 18 concluded that the NOAEL for males was 300 mg/kg/d and for females was 1000 mg/kg/d based on reported minor changes in liver weights, alanine aminotransferase, and liver histology dosed orally with dihydrocapsiate in rats. With the generation of chronic and recovery data in a 26-week study, the NOAEL for males was raised to 1000 mg/kg/d, the same as for females. 19 In comparison to the extensive safety data available on capsinoids and DHC in particular, there is no published information on the pharmacokinetics of these substances. As part of the development of capsinoids as a food ingredient, this single-dose (gavage) pharmacokinetic study of CH-19 Sweet extract was performed. The study was conducted in compliance with appropriate regulations ( 
Methods Animals
Male rats [Crj:CD(IGS) Specific Pathogen Free (SPF)] were purchased from Charles River Japan (Kanagawa, Japan). At the time of test article administration, the rats weighed between 204 and 223 g and were 7 weeks of age. The animals were housed in a SPF animal room under controlled conditions Sweet extract used in this study was 72%, 19%, and 9%, respectively. n-Hexane was used in the extraction process and is present in the final product at levels below the limit of detection (5 ppm). Compounds used as internal reference standards, capsiate, DHC, nordihydrocapsiate, and vanillyl undecanoate, were synthesized at Ajinomoto (Kawasaki, Kanagawa, Japan). Vanillyl alcohol (VOH) was purchased from Wako Pure Chemical (Osaka, Japan), and both b-glucuronidase/arylsulfatase (derived from Helix pomatia) and D-saccharic acid 1,4lactone were purchased from Sigma-Aldrich (St Louis, Mo). All the solvents and other chemicals used were of high-performance liquid chromatography (HPLC) grade or the highest purity commercially available.
Preparation of Dosing Formulation and Administration Method
CH-19 Sweet extract was diluted with medium-chain triglycerides, resulting in the production of 2 concentrations of capsinoids, 2 and 20 mg/mL. Rats were dosed at either 10 or 100 mg of capsinoids per kilogram of body weight. Rats were fasted for 16 hours before administration and dosed once by gavage using a stomach tube at a volume of 5 mL/kg of body weight.
Sample Collection
Serial blood samples were obtained from the portal vein and abdominal aorta under ether anesthesia at 5, 15, and 30 minutes and 1, 2 and 4 hours after administration (n ¼ 3 at each time point). Blood was drawn into tubes containing 20 mg/mL dichlorvos solution in 0.5 mmol/L sodium citrate buffer at pH 4.3 (Wako Pure Chemical) in a 1:10 ratio (dichlorvoscitrate buffer/blood). Plasma was prepared by centrifugation of the blood at 15 000 rpm for 5 minutes (Hitachi Koki, Tokyo, Japan). The sampling volume of blood was approximately 500 mL and 1000 mL from the portal vein and abdominal aorta, respectively.
Enzymatic Hydrolysis of Metabolites
The plasma, obtained from the abdominal aorta of 3 rats after single oral administration, was pooled and enzymatically hydrolyzed to investigate the conjugates. One milliliter of the plasma was mixed with 1 mL of 0.5 mol/L acetate buffer, pH 5.0 (Wako Pure Chemical) and 50 mL of b-glucuronidase (approximately 100 000 Fishman units/mL) and arylsulfatase (approximately 800 000 Roy units/mL). In the inhibition experiment, 20 mg of D-saccharic acid 1,4-lactone, a b-glucuronidase inhibitor, was added to the mixture and the mixture was incubated at 37 C for 4 hours to hydrolyze the conjugates. After incubation, the samples were treated as described later in this article.
Pretreatment for the Measurement of Capsinoids
An OASIS hydrophilic-lipophilic balance cartridge (60 mg/3 mL, Waters, Milford, Mass) was selected for the solid-phase extraction. The cartridge was activated using ethyl acetate (Junsei Chemical, Tokyo, Japan) and brought to equilibration with methanol (Junsei Chemical) and water prior to use. Then 100 mL of plasma was mixed with 10 mL of internal standard solution and 200 mL of acetonitrile (Junsei Chemical). After centrifugation, the upper layers were mixed with 950 mL of 20 mmol/L phosphate buffer at pH 3.0 (Wako Pure Chemical), and the mixture was applied to the solid-phase extraction cartridge. The cartridge was washed with 1 mL of 0.1% trifluoroacetic acid (TFA) solution (Wako Pure Chemical) and 30% acetonitrile aqueous solution. The analytes were eluted with 1 mL of ethyl acetate into a disposable glass tube containing 2 mL of DMSO (Junsei Chemical). The solvents were evaporated to dryness under a gentle stream of nitrogen at ambient temperature. The dried residue was reconstituted in a mixture of 20 mmol/L phosphate buffer (pH 3.0)/acetonitrile (50:50; vol/vol).
All the procedures executed prior to the application of the sample to the solid-phase extraction column were performed on ice and completed within 1 hour.
Pretreatment for the Measurement of VOH
An OASIS hydrophilic-lipophilic balance cartridge (30 mg/1 mL, Waters) was selected for the solid-phase extraction. The cartridge was activated using acetonitrile and brought to equilibration with water prior to use. Then 100 mL of plasma was mixed with 200 to 500 mL of 50 mmol/L phosphate buffer (pH 3.0) under ice-cold conditions, and the mixture was applied to the solid-phase extraction cartridge. The cartridge was washed with 1 mL of 0.1% TFA solution and 1 mL of 10% methanol solution. The analytes were eluted with 1 mL of acetonitrile into a disposable glass tube containing 2 mL of DMSO. The solvents were evaporated to dryness under a gentle steam of nitrogen at ambient temperature. The dried residue was reconstituted in 200 mL of water and injected into the HPLC.
Liquid Chromatography Tandem Mass Spectroscopy (LC-MS/MS) Analysis for Capsinoids
HPLC separation was performed using Agilent 1100 (Agilent Technologies, Santa Clara, California.) or Shimadzu 10A (Shimadzu, Kyoto, Japan) equipped with an Inertsil Ph-3 (4.6 mm inner diameter Â 150 mm, 3 mm GL-Science, Tokyo, Japan) analytical column and Sumipak Filter PG-ODS (4 Â 4 mm inner diameter, Sumika Chemical Analysis Service, Tokyo, Japan) guard filter. The mobile phase was a mixture of water/methanol (35:65; vol/vol) and the flow rate was maintained at 0.8 mL/min. The analytical cycle was maintained at 20 minutes or less. The HPLC system was connected to an API2000 MS/MS system (Applied Biosystems, Foster City, Calif), operated in APCI positive mode. The interface temperature was 450 C, and nitrogen was used as nebulizer and collision gas (collision energy, 31 eV); the corona discharge current was set to 2 mA. The MS/MS system was focused in multiple reaction monitoring (MRM) mode to monitor the ion as Q1: 137.1 and Q3: 94.2. Data collection and analysis were performed with Analyst (AB/MDS, Life Technologies Corp, California).
HPLC Analysis for VOH
The analysis of VOH in plasma was performed using a Shimadzu LC system, which included a DGU-14A degasser, LC-10ADVP pump, SIL-HTC auto-sampler, CTO-10AVP oven column, and SPD-10A UV detector (Shimadzu). A guard column (Inertsil Diol [3.0 mm inner diameter Â 10 mm, 5 mm] GL-Science, Tokyo, Japan), precolumn (Inertsil Diol [3.0 mm inner diameter Â 150 mm, 5 mm] GL-Science), and analytical column (Cadenza CL-C18 [3.0 mm inner diameter Â 150 mm, 3 mm] Imtakt, Kyoto, Japan) were used. These columns were assembled into a column-switching system. The mobile phase was a mixture of 20 mmol/L phosphate buffer (pH 7.0)/methanol (90:10, vol/vol), and the flow rate was 0.4 mL/min. The analytical cycle was maintained at 18 minutes or less. The eluted solution was monitored by absorbance at 280 nm. Data collection and analysis were performed using Class VP (6.12 SP3, Shimadzu).
Calculation of VOH Conjugate Concentrations
To investigate the concentration of sulfate and glucuronide VOH conjugates in plasma, the following analyses were performed:
1. The concentration of plasma VOH was determined following incubation with 0.5 mol/L acetate buffer, pH 5.0. 2. The concentration of plasma VOH was determined following incubation with 0.5 mol/L acetate buffer, pH 5.0, and b-glucuronidase. 3. The concentration of plasma VOH was determined following incubation with 0.5 mol/L acetate buffer, pH 5.0, b-glucuronidase, D-saccharic acid 1,4-lactone, and b-glucuronidase.
The concentration of the VOH sulfate conjugate was defined as the difference between items 3 and 1 above, whereas the concentration of the VOH glucuronide conjugate was defined as the difference between items 2 and 3.
Calculation of Pharmacokinetic Parameters
The maximum plasma concentration (C max ) and the time to attain C max (T max ) were calculated from the mean plasma concentrations at each time point. The area under the plasma concentration versus time curve (AUC 0-lim ) was calculated from the mean plasma concentrations at each time point by the trapezoidal method using Microsoft Excel. The plasma elimination half-life (t 1/2 ) was calculated as follows. The time points that reflected an elimination phase were obtained from the plasma concentration versus time curve. The mean plasma concentration values at each time point were converted to logarithmic values. Subsequently, a linear curve of the elimination phase was calculated based on the above (curve and log values) and using the method of least squares. Finally, a t 1/2 was calculated from the slope of the curve.
Results
The levels of the capsinoids in the portal vein and systemic blood of all rats (both 10 and 100 mg/kg) were below the limit of quantitation (LOQ; capsiate, DHC, and nordihydrocapsiate, 50 Zg/mL) at all time points examined. Thus, no pharmacokinetic parameters could be calculated for these compounds.
The plasma concentrations of free VOH determined in the portal vein and systemic blood of rats are presented in Table 1 . The LOQ for VOH was 20 ng/mL. The free VOH pharmacokinetic parameters derived from the Table 1 data are presented in Table 2 . The T max of VOH in the portal vein was 30 minutes after administration in both 10-and 100-mg/kg dose groups, whereas the C max achieved at T max was 0.163 mg/mL and 1.48 mg/mL, respectively. The AUC 0-4h in the 10and 100-mg/kg dose groups was 0.321 mgÁh/mL and 3.85 mgÁh/mL, respectively.
Because there were no appropriate time points reflecting an elimination phase based on the results of plasma concentrationtime profile, calculation of t 1/2 was not possible.
In rats dosed with 10 mg/kg, the systemic plasma concentrations of VOH were below the LOQ at all time points. In rats dosed with 100 mg/kg, the systemic plasma concentration of VOH was 0.0246 + 0.0241 mg/mL at 5 minutes after administration but fell below the LOQ at each time point thereafter. The AUC 0-5min for the 100-mg/kg group was 0.00103 mgÁh/mL; the t 1/2 could not be determined. Figure 3 and Table 3 show the time course of VOH conjugate concentrations. In the 10-mg/kg dose group, the concentrations of the sulfate conjugate were generally higher than the concentrations of the glucuronide. The AUC 0-4h of the
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International Journal of Toxicology 29(2S) VOH sulfate conjugate was 2.27 mgÁh/mL, whereas that of the glucuronide was 1.80 mgÁh/mL. In the 100-mg/kg dose group, the concentrations of sulfate conjugate of VOH were higher than the concentrations of the glucuronide at all the time points. The AUC 0-4h of the vanillyl alcohol sulfate conjugate was 18.2 mgÁh/mL and that of glucuronide was 8.94 mgÁh/mL.
Discussion
The results of this pharmacokinetic and metabolism study were obtained following a single gavage dose of CH-19 Sweet extract containing 7.5% capsinoids (equivalent to 10 or 100 mg of capsinoids per kilogram) to fasting male rats. No measureable levels of any of the capsinoids (ie, capsiate, DHC, and nordihydrocapsiate) were obtained in either the portal vein or systemic plasma at any study time points using an LOQ of 50 ng/mL. These findings are consistent with a previous study which reported that following a single gavage administration of 14 C-dihydrocapsiate to male rats, DHC was not detected in circulating plasma. 2 Similarly, a study in human volunteers reported that following an ingestion of up to 30 mg/kg capsinoid, neither capsinoids nor VOH was detectable in the plasma. 13 These results suggest that almost all, if not all, of the administered capsinoids were metabolized either in Each value represents mean + standard deviation of 3 individuals. Where the concentration of 2 or 3 of 3 cases was below the limit of quantitation (20 Zg/mL), the result is expressed as ND (not determined). When the concentration of 1 of 3 cases was below the limit of quantitation, the result is expressed as mean + standard deviation on the assumption that such value is zero (0). the gastrointestinal tract or alimentary mucosa or both prior to absorption into the portal vein. However, these data cannot exclude the possibility of extremely rapid metabolism in the portal vein.
The data further document that VOH, a metabolite of capsinoids, was found in the portal vein and had pharmacokinetic parameters (C max and AUC 0-4h ) that were approximately proportional to dosage. The apparent T max of VOH in the portal compartment (30 minutes) is in agreement with that reported (40 minutes) in a previous study. 20 VOH was, in turn, broken down (either prior to or immediately after its release into the systemic plasma) to sulfuric and glucuronic acid conjugates. Levels of both conjugates in the plasma were directly proportional to dose; that is, the plasma levels of both conjugates increased with increasing dose (ie, 10 vs 100 mg/kg). However, the plasma levels of the sulfuric conjugates were consistently higher than those of glucuronide in both dosage groups. This suggests that at least in rats, sulfuration plays a bigger role in the metabolism of VOH than does glucuronidation in rats. The proposed metabolic pathway for orally administered capsinoids is presented in Figure 4 .
Previously published toxicity and safety studies reported a lack of severe adverse effects following the administration of either CH-19 Sweet extract [9] [10] [11] [12] [13] 21 or DHC. [14] [15] [16] [17] [18] [19] [20] In one of these studies, 19 rats were administered 100, 300, and 1000 mg of DHC per kilogram per day for 26 weeks with resulting NOAELs of 1000 mg/kg/d for both sexes. This result suggests that VOH and VOH metabolites sulfuric and glucuronic acid conjugates, the metabolites of the capsinoids contained in CH-19 Sweet extract, when administered to rats, caused no severe adverse events at those doses.
A major component of capsinoids is DHC. A previous study 20 evaluated the metabolite profiles for DHC, both before and after enzymatic hydrolysis, and the results suggest that the compound is most likely to be metabolized in a multistep process. DHC is initially hydrolyzed to yield VOH and 8-methyloctanoic acid. Subsequently, the majority of the VOH is predominantly conjugated with glucuronic or sulfuric acid, whereas minor amounts are oxidized to vanillic acid.
In the only human clinical study reported for CH-19 Sweet extract, 13 the authors concluded that the consumption of either 15 or 30 mg of capsinoids per person was without clinically significant changes, and neither capsinoids nor VOH was detectable in the plasma. The pharmacokinetic results of the current rat study are consistent with and expand upon the findings previously reported in humans.
Conclusions
Based on the results of this study, a metabolic pathway for the capsinoids (capsiate, DHC, and nordihydrocapsiate) is suggested. The results are consistent with the rapid and apparently complete metabolism of capsinoids in the gastrointestinal tract and/or alimentary canal to VOH, although extremely rapid metabolism in the portal vein cannot be excluded by these data. VOH subsequently undergoes rapid and apparently complete metabolism, as demonstrated by the detection of sulfuric and glucuronic acid conjugates, not VOH, in the systemic plasma. These results are consistent with what is known regarding the human pharmacokinetics of capsinoids and support the preclinical toxicology and safety studies which suggest that capsinoids have a low potential for toxicity.
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